[
  {
    "ts": null,
    "headline": "Stocks to Watch Recap: Palantir, Coinbase, Gartner, Pfizer",
    "summary": "↗️ Palantir (PLTR): Shares in the data-software company were up 7.8% Tuesday after it posted higher quarterly results and boosted its annual outlook. ↘️Coinbase Global (COIN): Shares in the cryptocurrency exchange dropped 6.",
    "url": "https://finnhub.io/api/news?id=66e4a179243e670d4683f04ca455a55ec102cea57e1ec037f680a36d703f4223",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754428553,
      "headline": "Stocks to Watch Recap: Palantir, Coinbase, Gartner, Pfizer",
      "id": 136232239,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "↗️ Palantir (PLTR): Shares in the data-software company were up 7.8% Tuesday after it posted higher quarterly results and boosted its annual outlook. ↘️Coinbase Global (COIN): Shares in the cryptocurrency exchange dropped 6.",
      "url": "https://finnhub.io/api/news?id=66e4a179243e670d4683f04ca455a55ec102cea57e1ec037f680a36d703f4223"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More",
    "summary": "Palantir rose after earnings blew past Wall Street estimates. Shares of Vertex Pharmaceuticals and Hims & Hers plummeted on weak quarterly results.",
    "url": "https://finnhub.io/api/news?id=fc0f9c13adb94c4d4c3964eb3c845c00ff86e3d597a683e3c3bbca58fa6ff277",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754426640,
      "headline": "These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More",
      "id": 136232241,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Palantir rose after earnings blew past Wall Street estimates. Shares of Vertex Pharmaceuticals and Hims & Hers plummeted on weak quarterly results.",
      "url": "https://finnhub.io/api/news?id=fc0f9c13adb94c4d4c3964eb3c845c00ff86e3d597a683e3c3bbca58fa6ff277"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Dow Retreats After Back And Forth Action; Palantir Makes This Bold Move (Live Coverage)",
    "summary": "The Dow Jones Industrial Average and other major indexes ended the session in negative territory Tuesday, as investors reacted to plans for new chip tariffs from President Donald Trump. While a multitude of names saw large drops after earnings reports, IBD 50 name Palantir Technologies outperformed on the stock market today.",
    "url": "https://finnhub.io/api/news?id=646d2ca8f0e8c07be810830b94105ff71cf444dab1951233dbc64f6b0e0bb0d8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754425832,
      "headline": "Stock Market Today: Dow Retreats After Back And Forth Action; Palantir Makes This Bold Move (Live Coverage)",
      "id": 136217241,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "The Dow Jones Industrial Average and other major indexes ended the session in negative territory Tuesday, as investors reacted to plans for new chip tariffs from President Donald Trump. While a multitude of names saw large drops after earnings reports, IBD 50 name Palantir Technologies outperformed on the stock market today.",
      "url": "https://finnhub.io/api/news?id=646d2ca8f0e8c07be810830b94105ff71cf444dab1951233dbc64f6b0e0bb0d8"
    }
  },
  {
    "ts": null,
    "headline": "Why Vertex Pharmaceuticals (VRTX) Stock Is Trading Lower Today",
    "summary": "Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) fell 17.4% in the afternoon session after the company announced its experimental pain drug, VX-993, failed a key mid-stage clinical trial. The company’s experimental non-opioid painkiller, VX-993, failed to achieve a statistically significant pain reduction compared to a placebo in a mid-stage study. The trial involved patients who had undergone bunionectomy surgery. Following the failure, Vertex Pharmaceuticals stated it would stop",
    "url": "https://finnhub.io/api/news?id=576858bfbe231b655187a562db1a0e6995e1d02c055e29ce171c8f8ccaffb58e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754423450,
      "headline": "Why Vertex Pharmaceuticals (VRTX) Stock Is Trading Lower Today",
      "id": 136217242,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) fell 17.4% in the afternoon session after the company announced its experimental pain drug, VX-993, failed a key mid-stage clinical trial. The company’s experimental non-opioid painkiller, VX-993, failed to achieve a statistically significant pain reduction compared to a placebo in a mid-stage study. The trial involved patients who had undergone bunionectomy surgery. Following the failure, Vertex Pharmaceuticals stated it would stop",
      "url": "https://finnhub.io/api/news?id=576858bfbe231b655187a562db1a0e6995e1d02c055e29ce171c8f8ccaffb58e"
    }
  },
  {
    "ts": null,
    "headline": "VRTX: Vertex Shares Tank After Pain Drug Flop in Key Trial",
    "summary": "Vertex stock drops sharply after its pain drug fails a crucial clinical trial.",
    "url": "https://finnhub.io/api/news?id=9e03752f8edc9526a3be47f8a858f25b7eb8604dd29b63786bb7e7f874d700e0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754413208,
      "headline": "VRTX: Vertex Shares Tank After Pain Drug Flop in Key Trial",
      "id": 136215055,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex stock drops sharply after its pain drug fails a crucial clinical trial.",
      "url": "https://finnhub.io/api/news?id=9e03752f8edc9526a3be47f8a858f25b7eb8604dd29b63786bb7e7f874d700e0"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Dow Retreats After Back-And-Forth Action; Palantir Makes This Bold Move (Live Coverage)",
    "summary": "Stock Market Today: Dow Retreats After Back-And-Forth Action; Palantir Makes This Bold Move (Live Coverage)",
    "url": "https://finnhub.io/api/news?id=78c7615796e2494be484b09259ea2191686716747036d5aecd3dffdbbf498b5c",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754411432,
      "headline": "Stock Market Today: Dow Retreats After Back-And-Forth Action; Palantir Makes This Bold Move (Live Coverage)",
      "id": 136234797,
      "image": "",
      "related": "VRTX",
      "source": "DowJones",
      "summary": "Stock Market Today: Dow Retreats After Back-And-Forth Action; Palantir Makes This Bold Move (Live Coverage)",
      "url": "https://finnhub.io/api/news?id=78c7615796e2494be484b09259ea2191686716747036d5aecd3dffdbbf498b5c"
    }
  },
  {
    "ts": null,
    "headline": "CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption",
    "summary": "CRISPR Therapeutics posts a wider second-quarter loss tied to Sirius deal costs, while Casgevy adoption gains momentum across global markets.",
    "url": "https://finnhub.io/api/news?id=a106fd3da090e07853514caad212a7a55146a0b04c7a2a6e4d9a94e4fadb629c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754409240,
      "headline": "CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption",
      "id": 136215056,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "CRISPR Therapeutics posts a wider second-quarter loss tied to Sirius deal costs, while Casgevy adoption gains momentum across global markets.",
      "url": "https://finnhub.io/api/news?id=a106fd3da090e07853514caad212a7a55146a0b04c7a2a6e4d9a94e4fadb629c"
    }
  },
  {
    "ts": null,
    "headline": "Why Vertex Pharma Is Feeling The Pain Despite A Second-Quarter Beat",
    "summary": "Vertex stock nose-dived Tuesday after the biotech company said it wouldn't advance its next-generation pain drug into additional testing.",
    "url": "https://finnhub.io/api/news?id=61ccf71e889b31097d9c30d3fcd88aa7d14c7032a7a093937c88ced09f1deb04",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754408509,
      "headline": "Why Vertex Pharma Is Feeling The Pain Despite A Second-Quarter Beat",
      "id": 136215057,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex stock nose-dived Tuesday after the biotech company said it wouldn't advance its next-generation pain drug into additional testing.",
      "url": "https://finnhub.io/api/news?id=61ccf71e889b31097d9c30d3fcd88aa7d14c7032a7a093937c88ced09f1deb04"
    }
  },
  {
    "ts": null,
    "headline": "Top Stock Movers Now: Gartner, Axon Enterprise, Palantir, and More",
    "summary": "U.S. equities declined at midday following a soft services industry report and President Donald Trump's comments on new tariffs.",
    "url": "https://finnhub.io/api/news?id=ac5fdb358444616da5b61369d4bb48faefef9308be96ae36e17ad87c2672e541",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754408335,
      "headline": "Top Stock Movers Now: Gartner, Axon Enterprise, Palantir, and More",
      "id": 136214735,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "U.S. equities declined at midday following a soft services industry report and President Donald Trump's comments on new tariffs.",
      "url": "https://finnhub.io/api/news?id=ac5fdb358444616da5b61369d4bb48faefef9308be96ae36e17ad87c2672e541"
    }
  },
  {
    "ts": null,
    "headline": "VRTX Q2 Earnings Beat, Stock Down as Pain Drug Misses Study Goal",
    "summary": "Vertex beats second-quarter earnings and revenue estimates, but shares slide as pain drug VX-993 misses study goal.",
    "url": "https://finnhub.io/api/news?id=463f9c55291b9a7645313e4bdbb413801cefee4de694a61fb50df72911783f14",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754407980,
      "headline": "VRTX Q2 Earnings Beat, Stock Down as Pain Drug Misses Study Goal",
      "id": 136215059,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex beats second-quarter earnings and revenue estimates, but shares slide as pain drug VX-993 misses study goal.",
      "url": "https://finnhub.io/api/news?id=463f9c55291b9a7645313e4bdbb413801cefee4de694a61fb50df72911783f14"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Stock Tumbles After Strong Earnings. What’s Spooking Investors.",
    "summary": "Second-quarter adjusted earnings came in at $4.52 a share on revenue of $2.96 billion, beating expectations.",
    "url": "https://finnhub.io/api/news?id=6101a55c17638fd9c7f0904708aa62e114ffa0169cc887440b2f0383b83183de",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754403120,
      "headline": "Vertex Stock Tumbles After Strong Earnings. What’s Spooking Investors.",
      "id": 136215060,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Second-quarter adjusted earnings came in at $4.52 a share on revenue of $2.96 billion, beating expectations.",
      "url": "https://finnhub.io/api/news?id=6101a55c17638fd9c7f0904708aa62e114ffa0169cc887440b2f0383b83183de"
    }
  },
  {
    "ts": null,
    "headline": "Stocks See Support from Strong Earnings and Rate Cut Speculation",
    "summary": "The S&P 500 Index ($SPX ) (SPY ) today is up +0.11%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.24%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.20%. September E-mini S&P futures (ESU25 ) are up +0.15%, and September E-mini Nasdaq futures...",
    "url": "https://finnhub.io/api/news?id=a9d281e3b80f3e33180613ef2e96fe1ecb77140033ef9c6f16a67bb2d0afc822",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754402339,
      "headline": "Stocks See Support from Strong Earnings and Rate Cut Speculation",
      "id": 136215010,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "The S&P 500 Index ($SPX ) (SPY ) today is up +0.11%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.24%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.20%. September E-mini S&P futures (ESU25 ) are up +0.15%, and September E-mini Nasdaq futures...",
      "url": "https://finnhub.io/api/news?id=a9d281e3b80f3e33180613ef2e96fe1ecb77140033ef9c6f16a67bb2d0afc822"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Dow Rises Ahead Of Key Data; American Eagle, Coinbase Slide (Live Coverage)",
    "summary": "The Dow Jones index rose Tuesday ahead of key economic data. Palantir stock surged on strong earnings results.",
    "url": "https://finnhub.io/api/news?id=c52665bb9c72d79f6d3e90b95fcd9e7df5957a5c980340ca34504ba9714448a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754402064,
      "headline": "Stock Market Today: Dow Rises Ahead Of Key Data; American Eagle, Coinbase Slide (Live Coverage)",
      "id": 136212074,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "The Dow Jones index rose Tuesday ahead of key economic data. Palantir stock surged on strong earnings results.",
      "url": "https://finnhub.io/api/news?id=c52665bb9c72d79f6d3e90b95fcd9e7df5957a5c980340ca34504ba9714448a4"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug",
    "summary": "Shares of Vertex Pharmaceuticals sank 15% after the drugmaker announced a study showed its experimental pain medicine was not successful, and it would no longer move forward with its development.",
    "url": "https://finnhub.io/api/news?id=8c381f1081e6cb4d5513ed25d342954741a1e192f7bc0dc6a1ec9f6e7ffb3cdf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754401949,
      "headline": "Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug",
      "id": 136215062,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Shares of Vertex Pharmaceuticals sank 15% after the drugmaker announced a study showed its experimental pain medicine was not successful, and it would no longer move forward with its development.",
      "url": "https://finnhub.io/api/news?id=8c381f1081e6cb4d5513ed25d342954741a1e192f7bc0dc6a1ec9f6e7ffb3cdf"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals, Kyndryl, Caterpillar: Trending Tickers",
    "summary": "Vertex Pharmaceuticals (VRTX) stock is sliding after the company said it won't advance its pain treatment into the next phase of testing. Kyndryl's (KD) consulting revenue jumped 30%. Caterpillar (CAT) missed profit estimates and warned about the impact of tariffs. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
    "url": "https://finnhub.io/api/news?id=38f13eb055f004c94940fd1332330bb341c3555274a3a0797b97bea7201f12a7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754401290,
      "headline": "Vertex Pharmaceuticals, Kyndryl, Caterpillar: Trending Tickers",
      "id": 136212327,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (VRTX) stock is sliding after the company said it won't advance its pain treatment into the next phase of testing. Kyndryl's (KD) consulting revenue jumped 30%. Caterpillar (CAT) missed profit estimates and warned about the impact of tariffs. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
      "url": "https://finnhub.io/api/news?id=38f13eb055f004c94940fd1332330bb341c3555274a3a0797b97bea7201f12a7"
    }
  },
  {
    "ts": null,
    "headline": "Vortex Energy Mobilizes Field Crews for ANT Survey at Robinsons River Salt Project",
    "summary": "Field Crews Begin Deployment of Ant Sensors to Image Subsurface at Robinsons RiverVANCOUVER, British Columbia, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that field crews are mobilizing to the Robinsons River Salt Project in Newfoundland to initiate the deployment of Ambient Noise Tomography (“ANT”) sensors. This marks the start of the Company’s flagship geophysical survey designed to image the subs",
    "url": "https://finnhub.io/api/news?id=a0fa3b6c16ec725a9664f4f2199522a2d96958fb92c420c156dd76de3dc54b1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754395200,
      "headline": "Vortex Energy Mobilizes Field Crews for ANT Survey at Robinsons River Salt Project",
      "id": 136212451,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Field Crews Begin Deployment of Ant Sensors to Image Subsurface at Robinsons RiverVANCOUVER, British Columbia, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that field crews are mobilizing to the Robinsons River Salt Project in Newfoundland to initiate the deployment of Ambient Noise Tomography (“ANT”) sensors. This marks the start of the Company’s flagship geophysical survey designed to image the subs",
      "url": "https://finnhub.io/api/news?id=a0fa3b6c16ec725a9664f4f2199522a2d96958fb92c420c156dd76de3dc54b1e"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Tuesday: Palantir, BP, Pfizer",
    "summary": "↗️ Palantir (PLTR): The data-software company's stock rose 5% premarket after it posted higher quarterly profit and revenue. It also boosted its annual outlook. ↘️ Vertex Pharmaceuticals (VRTX): The biotechnology company said it wouldn't proceed with advanced testing of an experimental painkiller.",
    "url": "https://finnhub.io/api/news?id=1b16c775ae41d6af9bfa2ba96701e57a6c4a497e580a15207b822fea96898bd8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754383631,
      "headline": "Stocks to Watch Tuesday: Palantir, BP, Pfizer",
      "id": 136207516,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "↗️ Palantir (PLTR): The data-software company's stock rose 5% premarket after it posted higher quarterly profit and revenue. It also boosted its annual outlook. ↘️ Vertex Pharmaceuticals (VRTX): The biotechnology company said it wouldn't proceed with advanced testing of an experimental painkiller.",
      "url": "https://finnhub.io/api/news?id=1b16c775ae41d6af9bfa2ba96701e57a6c4a497e580a15207b822fea96898bd8"
    }
  },
  {
    "ts": null,
    "headline": "5 Things to Know Before the Stock Market Opens",
    "summary": "News of the day for August 5, 2025",
    "url": "https://finnhub.io/api/news?id=80bc0c3f89806406c78bd5fa23488cc7a0d998ae60750f15b3d3387682daf098",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754393782,
      "headline": "5 Things to Know Before the Stock Market Opens",
      "id": 136212266,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "News of the day for August 5, 2025",
      "url": "https://finnhub.io/api/news?id=80bc0c3f89806406c78bd5fa23488cc7a0d998ae60750f15b3d3387682daf098"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More",
    "summary": "Palantir rose after quarterly earnings blew past Wall Street estimates. Shares of Vertex Pharmaceuticals and Hims & Hers plummeted early Tuesday,",
    "url": "https://finnhub.io/api/news?id=1621d3fc2afd66eccad2db5c769d30a570e0d5c91158a0e77717021834347523",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754393220,
      "headline": "These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More",
      "id": 136212268,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Palantir rose after quarterly earnings blew past Wall Street estimates. Shares of Vertex Pharmaceuticals and Hims & Hers plummeted early Tuesday,",
      "url": "https://finnhub.io/api/news?id=1621d3fc2afd66eccad2db5c769d30a570e0d5c91158a0e77717021834347523"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Stock Tumbles 15% After Strong Earnings. What’s Spooking Investors.",
    "summary": "Second-quarter adjusted earnings came in at $4.52 a share on revenue of $2.96 billion, beating expectations.",
    "url": "https://finnhub.io/api/news?id=a58e520e10723de004a9066495123fb4aad3f8eefb64caf094f796922eb13e4b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754389080,
      "headline": "Vertex Stock Tumbles 15% After Strong Earnings. What’s Spooking Investors.",
      "id": 136212455,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Second-quarter adjusted earnings came in at $4.52 a share on revenue of $2.96 billion, beating expectations.",
      "url": "https://finnhub.io/api/news?id=a58e520e10723de004a9066495123fb4aad3f8eefb64caf094f796922eb13e4b"
    }
  },
  {
    "ts": null,
    "headline": "US stock futures higher amid mixed corporate earnings",
    "summary": "Palantir reported better-than-expected quarterly results, but restaurant chain Denny's and Hims & Hers Health posted disappointing results.",
    "url": "https://finnhub.io/api/news?id=a745381fa13279f91044830f15b9f51a8055dff02b4bde3e5ebcafa2cf6c7fa6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754388811,
      "headline": "US stock futures higher amid mixed corporate earnings",
      "id": 136212456,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Palantir reported better-than-expected quarterly results, but restaurant chain Denny's and Hims & Hers Health posted disappointing results.",
      "url": "https://finnhub.io/api/news?id=a745381fa13279f91044830f15b9f51a8055dff02b4bde3e5ebcafa2cf6c7fa6"
    }
  },
  {
    "ts": null,
    "headline": "S&P 500 Futures Climb in Premarket Trading; Vertex Pharmaceuticals, Gartner Lag",
    "summary": "S&P 500 Futures Climb in Premarket Trading; Vertex Pharmaceuticals, Gartner Lag",
    "url": "https://finnhub.io/api/news?id=46df4155b98e5c9cf4fa4c3fba9477430adbe20838109c73d2f4ae00f2440567",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754379060,
      "headline": "S&P 500 Futures Climb in Premarket Trading; Vertex Pharmaceuticals, Gartner Lag",
      "id": 136253495,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "S&P 500 Futures Climb in Premarket Trading; Vertex Pharmaceuticals, Gartner Lag",
      "url": "https://finnhub.io/api/news?id=46df4155b98e5c9cf4fa4c3fba9477430adbe20838109c73d2f4ae00f2440567"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc (VRTX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ...",
    "summary": "Vertex Pharmaceuticals Inc (VRTX) reports a 12% revenue increase and successful product launches, while addressing challenges in market access and R&D investments.",
    "url": "https://finnhub.io/api/news?id=44d9bcf2d3491c87e8b5f94a88db3d505ec6733f1a68ad3e4e1bd7a2599ac1b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754377416,
      "headline": "Vertex Pharmaceuticals Inc (VRTX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ...",
      "id": 136205903,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals Inc (VRTX) reports a 12% revenue increase and successful product launches, while addressing challenges in market access and R&D investments.",
      "url": "https://finnhub.io/api/news?id=44d9bcf2d3491c87e8b5f94a88db3d505ec6733f1a68ad3e4e1bd7a2599ac1b7"
    }
  },
  {
    "ts": null,
    "headline": "Vertex plan to build on pain drug breakthrough hits hurdles",
    "summary": "The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain would take more testing. A successor medicine, meanwhile, fell short in Phase 2.",
    "url": "https://finnhub.io/api/news?id=660f6bf838eaf0c9fcdde9b98689a5c1219a9c59e05b5f930de024c5c5b6b629",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754375460,
      "headline": "Vertex plan to build on pain drug breakthrough hits hurdles",
      "id": 136212458,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain would take more testing. A successor medicine, meanwhile, fell short in Phase 2.",
      "url": "https://finnhub.io/api/news?id=660f6bf838eaf0c9fcdde9b98689a5c1219a9c59e05b5f930de024c5c5b6b629"
    }
  },
  {
    "ts": null,
    "headline": "Palantir shares hit new record after earnings, and other early market movers",
    "summary": "Palantir shares hit new record after earnings, and other early market movers",
    "url": "https://finnhub.io/api/news?id=b99819519425a1ec4c2089bcfcea8b7abd972c4f76e903d4905b6dd73268e69b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754372944,
      "headline": "Palantir shares hit new record after earnings, and other early market movers",
      "id": 136234823,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Palantir shares hit new record after earnings, and other early market movers",
      "url": "https://finnhub.io/api/news?id=b99819519425a1ec4c2089bcfcea8b7abd972c4f76e903d4905b6dd73268e69b"
    }
  }
]